KLRC2 and non-Hodgkin lymphoma: In summary, we have identified that the progression to EBV+HL and EBV+nHL in the individual patients was highly associated with a potent inhibitory NKG2A/LMP-1/HLA-E pathway, but absent pro-inflammatory NKG2C+ NK cell responses.